VerifyMe amends 8-K to correct Legacy OpenWorld share issuance to 11,686,124 shares
Bitget2026/10/02 12:01- VerifyMe filed an amended 8-K to correct errors in its Sept. 30 merger disclosure with Legacy OpenWorld.
- Legacy OpenWorld equity holders received 11,686,124 shares, not 11,621,124 shares, at the merger’s effective time.
- Consultants and partners received warrants for 300,000 shares, not 100,000 shares, tied to the Nasdaq listing.
- The filing stated no other changes were made to the original 8-K.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
3D printing materials supplier Amaero (AMRO.US) restarts US IPO, fundraising drops 60% to $20 million
Amaero (AMRO.US) on Thursday resumed its initial public offering (IPO) plans in the United States and filed new documents with the U.S. Securities and Exchange Commission (SEC), revealing a reduced number of shares to be issued.
Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.
Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.
Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.
Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.
Crypto prices
More
